Blackstone will provide up to $1.5 billion through 2028 to support Pfizer's development of berobenatide, an experimental monthly obesity treatment. Drug DevelopmentHealthcare InvestmentObesity TreatmentThe funding will support the development of berobenatide through 2028, with Blackstone eligible for milestone-based payments but no ownership rights in the drug. Editorial Note: This content has been prepared using information from official announcements, regulatory communications, scientific publications, conference presentations, or other verified sources.